胶质瘤细胞的ERCC-2基因表达和氯乙基亚硝脲耐药  

ERCC-2 Gene expression and chloroethylnitrosourea in 9 human glioma cell lines

作　　者：陈忠平[1] GerardMohr LawrencePanasci 黄强[1] 

机构地区：[1]苏州医学院附二院神经外科,215004 [2]SirMortimerBDavis-JewishGeneralHospital,NcGillUniversityMontreal,Canada

出　　处：《中华神经外科杂志》1999年第6期365-367,共3页Chinese Journal of Neurosurgery

摘　　要：目的探讨核苷酸切除修复交叉互补（ＥＲＣＣ）基因表达与肿瘤细胞对氯乙基亚硝脲（ＣＥＮＵ）耐药的关系。方法采用我们已建立的逆转录．聚合酶连锁反应（ＲＴ－ＰＣＲ）定量分析方法，对９株人胶质瘤细胞的ＥＲＣＣ－２基因表达进行测定，并与ＣＥＮＵ细胞毒性试验进行相关分析。结果ＥＲＣＣ－２基因表达与二氯乙基亚硝脲（ＢＣＮＵ）及二氯乙基肉芥子亚硝脲（ＳａｒＣＮＵ）耐药性之间有显著的正相关（ｒ＝０．６７２，Ｐ＝０．０４７和ｒ＝０．７２６，Ｐ＝０．０２８）。结论本研究提示ＥＲＣＣ－２基因表达在胶质瘤对亚硝脲类抗癌药耐药中起重要作用。Objective To investigate concordance between nucleotide excision repair(NER)gene expressionand chloroethylnitrosourea (CENU) resistance in human tumor cell lines. Methods ERCC-2 gene expressions in9 human glioma cell be were evaluated by using an established quantitative revese-transcription polymerase chain reaction (RT-PCR). Correlation analysis between the results and CENU cytotoxicities was done. Results There wasa significant correlation between ERCC-2 gene expression and BCNU or SarNU cytotoxicity (r=0.672, P=0.047and r=0.726, P=0.028 respectively). Conclusion Our results suggest that ERCC-2 gene expression may playan important role in nitrosoureas drug resistance in human gliomas

关 键 词：脑肿瘤 胶质瘤 ERCC-2 基因表达 CENU 药物疗法 

分 类 号：R739.410.5[医药卫生—肿瘤]